Trials Sponsors Conditions Drugs Pricing

Conditions

Female Infertility Associated With Anovulation

Keywords

pcoAmlodipine

Outcome Measures

Primary Outcomes (1)

change in ovarian artery perfusion
peak systolic velocity ( psv ) measured by doppler u/s
day number five and day number 9 of menstrual cycle

Secondary Outcomes (2)

Number of mature follicle
day 14 of menstrual cycle
endometrial thickening
day number five and day number 9 of menstrual cycle

Study Arms (2)

Clomifene citrate and Amlodipine

EXPERIMENTAL

Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.

Drug: Clomifene citrate ( clomid 50 mg )Drug: Amlodipine

Clomifene citrate

ACTIVE COMPARATOR

Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9

Drug: Clomifene citrate ( clomid 50 mg )

Interventions

Clomifene citrate ( clomid 50 mg )Drug

Also known as: clomid ( 50 mg )

Clomifene citrateClomifene citrate and Amlodipine

AmlodipineDrug

Also known as: Norvasc 5mg

Eligibility Criteria

Age20 Years - 35 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Demographic features including females in age of ≥20 \& ≤35, and BMI of ≤39.
Infertility secondary to polycystic ovary , The choice of polycystic ovary patients will be according to the Rotterdam consensus workshop (Rotterdam, 2004), and the diagnosis of polycystic ovary by ultrasonography will be made according to Adams et al. criteria which are the most often cited (Adams et al., 1985).The Rotterdam criteria as follows:

Sponsors & Collaborators

Ahmed Fathy Ali Mohamed Ghanem
Otherlead

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Interventions

ClomipheneAmlodipine

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal Disorders

Enrollment

60 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: SINGLE
Who Masked: PARTICIPANT
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Resident of Obstetrics and Gynecology

Study Record Dates

First Submitted

August 27, 2015

First Posted

September 9, 2015

Study Start

January 2015

Date type not reported

This date has not been verified as actual or estimated.

Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

First Submitted

Study Completion

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Clomifene citrate and Amlodipine

Clomifene citrate

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

Study Completion

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Clomifene citrate and Amlodipine

Clomifene citrate

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record